Psilocybin Microdosing on Cognition, Mood and Quality of Life Trial

Bottom line: A small, early-phase trial is investigating whether psilocybin microdosing may be associated with subtle changes in brain function, mood, and cognition over 30 days, though results are not yet available.

A small trial is testing whether daily microdoses of psilocybin — at levels too low to trigger a full psychedelic experience — might subtly influence brain function and mental well-being over 30 days. This is one of the first studies to examine microdosing’s potential effects on brain structure and function in a controlled setting.

What’s being tested

The trial is comparing the effects of intermittent psilocybin microdosing — given at sub-perceptual doses — to a placebo, over a 30-day period. Researchers are looking for measurable changes in mood, cognition, and subjective well-being, without participants experiencing a full psychedelic trip. The study is designed to see if microdosing might offer small but detectable benefits for mental health and cognitive function.

The design at a glance

This is an Early Phase 1 trial, currently not yet recruiting participants, and is sponsored by Yale University. Early Phase 1 trials typically focus on safety, tolerability, and basic effects of an intervention in a small group of healthy volunteers. The study will compare the effects of psilocybin microdosing against a placebo, using a structured 30-day regimen. Participants will have their mood, cognition, and subjective well-being assessed, along with structural and functional MRI scans to see if there are changes in brain activity and connectivity.

Why it matters

If the trial shows that microdosing psilocybin leads to measurable changes in brain structure or function — without the full psychedelic experience — it could help explain how psychedelics interact with the brain. This might shed light on the mechanisms behind microdosing’s potential therapeutic uses, such as improving mood, increasing cognitive flexibility, or enhancing overall well-being. This could be especially relevant for people looking for non-invasive, low-risk options for mental health or cognitive enhancement.

What this does NOT mean yet

It’s important to note that this trial is not yet recruiting and has no results to report. Registration on ClinicalTrials.gov doesn’t mean the intervention is safe, effective, or endorsed by the FDA or any other regulatory body. Early Phase 1 trials focus on safety and basic effects, and many of them don’t move forward to later phases. Until the trial is completed and results are published, no conclusions about the effectiveness or benefits of psilocybin microdosing can be made.

How to follow it

For updates on this trial, visit the ClinicalTrials.gov record at https://clinicaltrials.gov/study/NCT07449351. Results will be posted there once the trial is completed and data is analyzed.

Sources

https://clinicaltrials.gov/study/NCT07449351 | NCT07449351

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.